Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Apotex Corp., priced at $0.7946 per EA under NDC 60505434806. Its NADAC has been published 131 times since Apr 3, 2024.
FDA first approved this application on Dec 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Apotex Corp.NDC
60505434806
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208070FDA Approved
12/15/2023
TE Code
AB
On Market Since
2/13/2024
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 131 times since Apr 3, 2024, and over the history we have for it it has declined 71.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7946 per EA |
|---|---|
| All-time high | $2.8528 (Jul 10, 2024) |
| All-time low | $0.7946 (Sep 23, 2026) |
| 52-week high | $1.1459 |
| 52-week low | $0.7946 |
| Median price | $1.4231 |
| Average price | $1.4963 |
| Largest weekly change | +47.0% (Jun 19, 2024) |
| Weeks tracked | 131 |
| Tracking since | Apr 3, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dabigatran etexilate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apotex Corp. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dabigatran etexilate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Direct Thrombin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Apotex Corp., is $0.7946 per EA (NDC 60505434806), effective Sep 30, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 71.8%. It has been tracked across 131 weekly CMS publications since Apr 3, 2024.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Apr 3, 2024, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.7946 (Sep 23, 2026) to a high of $2.8528 (Jul 10, 2024), with a median of $1.4231 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 150 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 60505434806) is labeled by Apotex Corp., and CMS classifies it as a generic product.